Medicine extended lifespan. It did far less for the aging mind.
Modern medicine extended how long we live. It did far less for the aging mind. Late-life neuropsychiatric disease now defines how those decades are lived, across distinct categories, each underserved. That is why the right vehicle is a studio, not a single drug.
Starting from scratch in neuropsychiatry is slow and fails often. You cannot ask a mouse how it feels, which is why the drugs that can reach this generation are ones with histories of human use and a measurable clinical endpoint.
More than 150,000 people cross into late life every day. Each carries decades that medicine has extended but not yet made worth living, across category after underserved category.
Derived from UN World Population Prospects (approximately 55 million people reach age 65 each year).
Development left unfinished. Ours to complete.
We don't start from zero. We rediscover.
Palomar modernizes overlooked drugs with prior human exposure, secures new IP, and builds a category-owning company around each rediscovered asset, then does it again, behind the next drug.
Start from zero. Target biology first, human relevance years away, high capital committed before the first patient.
Start from human evidence. Prior human safety data, an earlier clinical path, and new IP around a better indication, formulation, or analog.
Many were not failed drugs. They were stranded by prior-era endpoints, market timing, weak sponsorship, or a lack of category focus. Four gates before we build:
Underwriters, not advocates.
We kill the many quickly and carry the few to value inflection. The first experiment is the cheapest one that can kill the program.
The edge is not the archives. It is the combination: proprietary inputs, the partnership's judgment and bench, the IP wrapped around each asset, and the speed to execute.
NAXOS surfaces. The partnership decides.
NAXOS is disciplined sourcing and scoring, not the decision and not automation. The point is breadth, memory, and disciplined triage: proprietary sources others overlook, scoring against a known benchmark, and a partnership that makes every advance-or-kill call.
A small set of top-tier assets. NAXOS surfaces them; the partnership makes every advance-or-kill call.
Programs at inflection.
Proof of the model, not ahead of it. Each program is a rediscovered asset carried toward its first clinical readout.
There is no FDA-approved therapy for apathy in Parkinson’s disease. AB-300 is an investigational therapy for apathy in Parkinson’s disease and late-life depression.
Non-sedating control of agitation and aggression, beginning at a defined lead indication with no approved therapy and extending by mechanism to broader behavioral disturbance associated with neurodegeneration.
A rediscovered drug with extensive prior human exposure, in diligence for vitality and late-life function.
Own by vacancy, then own by differentiation.
Each class begins at a beachhead with no approved therapy, then expands by mechanism into a platform across related conditions.
The people behind the model.
The partnership combines biotech company formation, CNS drug development, serotonergic and CNS pharmacology, venture investing, and regulatory execution.
Capital-efficient serial founders and proven biotech operators who hold their own capital in the vehicle, alongside investors.
Serial founder and venture investor; 25+ CNS and neuroscience deals and 3 exits.
LinkedIn
Founder and CEO, Eleusis; President, Beckley Psytech; Goldman Sachs MD.
LinkedIn
Former VP Ops and co-CEO of multiple biopharmas; PhD, Weizmann Institute.
LinkedIn
Scientist-founder at the intersection of chemistry and venture; former Roivant; PhD Vanderbilt, postdoc Harvard.
LinkedInPrior exits and licensing reflect companies with which team members were affiliated, not attributable to Palomar Labs or its current portfolio.
Veteran of CNS drug discovery; leadership roles at Genentech, Regeneron, and Otsuka.
LinkedInBacked by a standing bench of scientific, clinical, and regulatory advisors.
Advisor and combined-years figures are approximate, derived from public professional histories and rounded.
Get in touch.
For partners, advisors, press, and inquiries. We read everything that comes through.